Pharmacogenomics study of anti-tuberculosis drugs in the Asian population
Description: We have been conducting International Collaborative TB Research in Asia. Anti-TB drug-induced liver injury (AT-DILI) is a main reason of treatment failure. A total of 138 Thai TB patients including 53 AT-DILI cases and 366 Japanese TB patients including 73 AT-DILI cases were enrolled. The odds ratios of N-acetyltransferase 2 (NAT2) slow acetylator (SA) status with AT-DILI were 8.80 (95% confidence interval (CI) 4.01-19.31, P-value = 1.53*10-8) in Thais and 4.32 (95%CI 1.93-9.66, p=5.56*10-5) in Japanese. Our results demonstrated that the acetylator status of NAT2 is an important determinant for AT-DILI in Asia. We performed first-phase genome-wide association study to search for the additional genetic factors. International meta-analysis and cost-effectiveness analysis may provide data to support the individualization of anti-TB treatment in Asian TB patients based on genotyping of the NAT2 and additional genes.
Amount: ¥17,290,000
Funding type: research
Funder scheme: Grant-in-Aid for Scientific Research (B)
Start date: 2012-04-01
End date: 2015-03-31
Investigator: Katsushi TOKUNAGA (lead)
Institution: The University of Tokyo
Subfield: Pharmacology
Domain: Life Sciences
Funded outputs count: 6
Funder award ID: 24406010
OpenAlex ID: G192405422